Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for Ureteral Stent-related Pain (MAP)
NCT04286152Phase 3Unknown
- Sponsor
- Unity Health Toronto
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ureteral stent-related symptoms (USRS) comparing Mirabegron with Placebo (2 arms). Primary endpoints: Visual Analog Scale Pain Score at 7 days and Ureteral Stent Symptom Questionnaire Pain Score at 7 days. Status: unknown.
02
Drugs
mirabegron
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on NCT04286152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04286152.